AcuCort

In addition to previously committed subscriptions, the Chair of the Board, Ebba Fårhaeus, has entered into a subscription commitment for an additional approximately SEK 200,000. These commitments are made on the same terms as for other investors. Through these commitments, the leadership demonstrates its continued confidence in AcuCort’s future prospects. On 14 January 2025, it was announced that the Company’s CEO, Jonas Jönmark, had increased his subscription commitment to a total of approximately SEK 2 million.

In total, subscription commitments from the board, management, and major shareholders now amount to SEK 16 million, corresponding to approximately 33 per cent of the rights issue. The subscription period for the rights issue runs from 9 January 2025 to 24 January 2025.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.